कृपया अन्य खोज का प्रयास करें
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Quan Dong Nguyen | - | 2021 | Member of the Scientific Advisory Board |
Adrian Vella | - | 2021 | Member of the Scientific Advisory Board |
Gilbert M. Labrucherie | 51 | 2019 | Independent Director |
Alvin Schmaier | - | - | Member of the Scientific Advisory Board |
Nevan Charles Elam | 57 | 2013 | Founder, CEO & Acting Chairman of the Board |
Jerrold M. Olefsky | - | 2014 | Member of the Scientific Advisory Board |
Robert B. Bhisitkul | - | - | Member of the Scientific Advisory Board |
Nerissa C. Kreher | 50 | 2021 | Independent Director |
Young-Jin Kim | 68 | 2019 | Director |
Philippe Fauchet | 67 | 2020 | Independent Director |
Wladimir Hogenhuis | 58 | 2021 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है